Microbot Medical expands U.S. operations to prep for first in-human clinical study
Microbot Medical’s LIBERTY system is a single-use endovascular robotic surgical system. | Source: Microbot Medical Microbot Medical Inc., the developer of the LIBERTY Endovascular Robotic Surgical System, is building on the momentum from the positive results of its good laboratory practices, or GLP, pre-clinical study. The company is adding a clinical research associate to support its pending investigational device exemption, or IDE, submission to commence its first-in-human clinical trial. The clinical research associate (CRA) will join the Braintree Mass.-based company ‘s established clinical team in the U.S. The team is led by Dr. Juan Diaz-Cartelle, chief medical officer of Microbot Medical. “Following the successful completion of our pivotal GLP pre-clinical trial, and as we are in the final stage of submitting our IDE, having an in-house CRA is a key piece for establishing the right infrastructure for clinical trial execution” said Diaz-Cartelle in a release . L...